Inhibitex Investor Sues To Block $2.5B Bristol-Myers Deal

Law360, Wilmington (January 12, 2012, 3:50 PM EST) -- An Inhibitex Inc. shareholder launched a class action in Delaware state court on Wednesday challenging Bristol-Myers Squibb Co.'s $2.5 billion bid to acquire the biopharmaceutical company and its clinical-stage hepatitis C drug, despite the offer’s hefty premium.

The two companies announced the $26-per-share merger agreement on Jan. 7 — an offer well over double Inhibitex’s closing price of $9.87 on the previous trading day.

But in a suit filed in Delaware Chancery Court, shareholder Charles Osborne alleged that the price still did not represent Inhibitex’s true...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.